Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression

Jenny Karlsson; Anders Valind; Caroline Jansson; Maureen J. O’Sullivan; Linda Holmquist Mengelbier; David Gisselsson

doi:10.18632/oncotarget.7152

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression

Jenny Karlsson _, Anders Valind, Caroline Jansson, Maureen J. O’Sullivan, Linda Holmquist Mengelbier and David Gisselsson

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:11127-11136. https://doi.org/10.18632/oncotarget.7152

Metrics: PDF 1460 views | HTML 1778 views | ?

Abstract

Jenny Karlsson1,*, Anders Valind1,*, Caroline Jansson1, Maureen J. O’Sullivan2, Linda Holmquist Mengelbier1, David Gisselsson1,3

1Department of Clinical Genetics, Lund University, University and Regional Laboratories, Lund, Sweden

2National Children’s Research Centre, Our Lady’s Children’s Hospital, Crumlin, Dublin 12, Ireland

3Department of Pathology, Skåne Regional and University Laboratories, Lund, Sweden

*These authors have contributed equally to this work

Correspondence to:

Jenny Karlsson, e-mail: [email protected]

Keywords: CCSK, Wilms tumor, pediatric tumors, hypermethylation, EZH2

Received: September 30, 2015 Accepted: January 23, 2016 Published: February 03, 2016

ABSTRACT

The global methylation profile and the mutational status of 633 specific epigenetic regulators were analyzed in the pediatric tumor clear cell sarcoma of the kidney (CCSK). Methylation array analyses of 30 CCSKs revealed CCSK tumor DNA to be globally hypermethylated compared to Wilms tumor, normal fetal kidney, and adult kidney. The aberrant methylation pattern of CCSKs was associated with activation of genes involved in embryonic processes and with silencing of genes linked to normal kidney function. No epigenetic regulator was recurrently mutated in our cohort, but a mutation in the key epigenetic regulator EZH2 was discovered in one case. EZH2 mRNA was significantly higher in CCSK compared to Wilms tumor and normal kidney, and the EZH2 protein was strongly expressed in more than 90 % of CCSK tumor cells in 9/9 tumors analyzed. This was in striking contrast to the lack of EZH2 protein expression in Wilms tumor stromal elements, indicating that EZH2 could be explored further as a diagnostic marker and a potential drug target for CCSK.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7152

Publication Alerts

Research Papers:

Aberrant epigenetic regulation in clear cell sarcoma of the kidney featuring distinct DNA hypermethylation and EZH2 overexpression

Abstract